We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Probucol Protects Arteries by Inhibiting Two-Electron Oxidant

By Biotechdaily staff writers
Posted on 01 May 2006
Researchers studying coronary artery disease have found that inhibition of free radicals had little effect on preventing heart disease while treatment of two-electron oxidants retarded development of atherosclerosis.

While antioxidants such as beta-carotene and vitamin E have failed in clinical trials to protect against heart disease, the drug probucol had been found to slow the development of atherosclerosis in carotid arteries and restenosis of coronary arteries after angioplasty.

To determine probucol's mode of operation, investigators at the University of New South Wales (Sydney, AU) created laboratory models for three types of coronary artery disease. More...
The models comprised apolipoprotein E–deficient mice, a model of atherosclerosis; rabbit aortic balloon injury, a model of restenosis; and carotid injury in obese Zucker rats, a model of type 2 diabetes. Animals in each group were treated with probucol, its sulfur-containing metabolite, or a sulfur-free phenolic analogue.

Results published in the April 10, 2006, online edition of the Journal of Experimental Medicine showed that probucol and its sulphur-containing metabolite, but not the sulphur-free phenolic analogue, protected the arteries via cell-specific effects on inhibiting macrophage accumulation, stimulating re-endothelialization, and inhibiting vascular smooth muscle cell proliferation. These effects were found to be mediated via induction of heme oxygenase-1 (HO-1), an activity not shared by vitamin E.

The authors concluded that, "Two-electron rather than radical [one-electron] oxidants are important contributors to atherogenesis, and point to novel lead compounds for therapeutic intervention against atherosclerotic diseases.”



Related Links:
University of New South Wales

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Automatic CLIA Analyzer
Shine i6000
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Blood Test Measuring Tumor Proliferation May Guide Treatment Sequencing in Metastatic Melanoma

Metastatic melanoma remains difficult to manage because outcomes vary widely and early prognostic markers are limited. About half of patients carry a BRAF gene mutation, giving clinicians several first-line... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Comprehensive Genomic Testing Expands Treatment Options for Advanced Cancers

Selecting effective therapies for advanced cancers remains difficult because standard tumor testing often targets only a limited set of genes. As options dwindle, many patients face decisions without strong... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.